OrganiGram Holdings Inc Stock News

Organigram reported Q4-2024 financial results earlier this week and show improved revenues, profit margins, net loss, and increased cash. The company announced the acquisition of Canadian private cannabis LP Motif Labs which will set Organigram in the top spot in Canada by market share. Organigram has increased its international footprint with an investment in Sanity Group in Germany and in Ope...

Organigram Holdings Inc. (NASDAQ:OGI ) Q3 2024 Earnings Conference Call December 18, 2024 8:00 AM ET Company Participants Max Schwartz - Director of IR Beena Goldenberg - CEO Tim Emberg - CCO Greg Guyatt - CFO Conference Call Participants Aaron Grey - Alliance Global Partners Frederico Gomes - ATB Capital Markets Pablo Zuanic - Zuanic & Associates Yewon Kang - Canaccord Genuity Operator Good mo...

Legal cannabis company grows revenue and narrows its loss as it continues its acquisition push.

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer (“LP”) of cannabis, announced its results for the fourth quarter and twelve months ended September 30, 2024 (“Q4 Fiscal 2024” or “Fiscal 2024”). All financial information in this press release is expressed in Canadian dollars (“$”). Comparable Periods: The Co...

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open. The Company will host a confer...

OrganiGram to pay up to C$100 million ($70.7 million) for vape and prerolled cannabis specialist Motif.

TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Motif Labs Ltd. (“Motif”), for upfront consideration of $90 million, consisting of $50 million in cash and $40 million of Organigram common shares priced based...

Organigram's stock is undervalued, trading at a 22% discount to tangible book value, with strong growth projections and a solid financial outlook. The company has a high cash balance and no debt, bolstered by additional investment from British American Tobacco. Analysts expect revenue and adjusted EBITDA to grow significantly in FY25 and FY26, making the stock a compelling buy.